Physician profile
Timinder S Biring
NPI 1487621017
$43,472.04
in general payments reported to CMS, 2019-2025
14 companies · $7,215 in 2025
The $7,215 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,389 · 2020: $1,046 · 2021: $4,125 · 2022: $16K · 2023: $4,253 · 2024: $2,577 · 2025: $7,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,288 · Food and Beverage: $3,395 · Travel and Lodging: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,287.50 |
| Food and Beverage | $3,394.59 |
| Travel and Lodging | $1,362.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,888.47 | 2019-2025 | General - Structural Heart, Avvigo Guidance System, Watchman Flx |
| Medtronic Vascular, INC. | $8,175.15 | 2019-2020 | |
| Shockwave Medical, INC | $8,023.14 | 2020-2025 | |
| Medtronic, INC. | $4,670.75 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Cordis US Corp. | $4,500.00 | 2022 | |
| Arrow International, INC. | $4,021.98 | 2019-2023 | |
| Teleflex LLC | $2,491.70 | 2022-2024 | Manta, Guideliner |
| Edwards Lifesciences Corporation | $337.23 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $190.44 | 2021-2025 | Diamondback Coronary, Optis |
| Siemens Medical Solutions USA, INC. | $90.79 | 2021 | |
| Philips North America LLC | $44.14 | 2025 | Coronary Other |
| Abiomed | $26.27 | 2025 | |
| Chiesi USA, INC. | $11.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timinder Biring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.